STAT
APRIL 4, 2024
It began with injecting monkeys with sewage to see if they developed polio. Building off that early polio work from the 1940s, researchers from the Baylor College of Medicine analyzed public wastewater and showed they could detect over 450 disease-causing viruses. Their study demonstrating the power of sewage as an early-warning system for outbreaks won the 2024 STAT Madness popular vote.
PharmaVoice
APRIL 4, 2024
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 4, 2024
Humans have long tinkered with the evolutionary trajectories of other species. Thousands of years ago we tamed wolves into dogs and transformed a wild grass into the agricultural wonder wheat. Within the past few centuries, we exterminated the Tasmanian tiger and doomed the dodo bird to oblivion. Now, we stand on the brink of an ambitious new era in how humans may transfigure life around us: by pursuing the science of de-extinction, or the resurrection of species once lost to this world.
pharmaphorum
APRIL 4, 2024
President Joe Biden has reiterated his pledge to take action against high drug prices and “beat big pharma,” singling out the cost of asthma inhalers in a speech delivered at a White House event with US Senator Bernie Sanders, a long-time critic of the industry’s pricing policies in the US.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
APRIL 4, 2024
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug , Relyvrio, after a large clinical trial showed that the medicine, approved by the Food and Drug Administration in 2022, was not effective. Amylyx’s co-CEOs, Joshua Cohen and Justin Klee, had previously publicly promised that they would withdraw the drug if further testing failed to show a benefit.
pharmaphorum
APRIL 4, 2024
Discover how AI-powered real-world evidence generation is revolutionising the biotech industry, providing valuable insights for biopharma companies to make informed decisions. Learn more about the impact of RWD on biotechs.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
APRIL 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field.
Pharmafile
APRIL 4, 2024
Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), as a new antibiotic for three indications. The drug is approved for the treatment of adult patients with Staphylococcus aureus bloodstream infections (SAB), including patients who have right-sided infective endocarditis, adult patients with acute bacterial […] The post FDA approves Basilea’s antibiotic Zevtera for three indications appeared
STAT
APRIL 4, 2024
The oversight division of a U.S. government agency tasked with ensuring the safe use of radioactive materials issued a recent report that the agency’s advisers had key undisclosed conflicts of interest, raising fresh concerns about controversial decisions around the reporting of radioactive injection accidents. The report, released on March 26 and conducted by the Nuclear Regulatory Commission’s (NRC) Office of the Inspector General, identified conflicts of interest involving two m
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
pharmaphorum
APRIL 4, 2024
Healthcare system Providence has spun out a new company, Praia Health, focused on a platform to build and sustain connections between patients and health providers. The new company starts life with $20 million in Series A funding and a mission to develop the Praia Health Identity and Engagement Platform, which was launched within Providence’s digital innovation group (DIG) incubator in 2022 and already handles around 3.5 million user accounts.
STAT
APRIL 4, 2024
For more than a century, the United States has been the undisputed leader in medical and biotechnology innovation. It saved millions of lives by mass-producing the first polio vaccines. U.S. researchers discovered new antibiotics that turned once-fatal infections into minor ailments, and developed antiretroviral cocktails that transformed HIV from a death sentence into a manageable, chronic disease.
BioPharma Dive
APRIL 4, 2024
A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.
STAT
APRIL 4, 2024
Many of the effects of climate change play out at a very large scale: Heatwaves that grip entire continents. Flooding that submerges vast swaths of island nations and continental coastal areas. Other effects are far less visible because they’re taking place inside people’s bodies. That doesn’t make them any less dangerous.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
European Pharmaceutical Review
APRIL 4, 2024
A new £17.9 million initiative announced on 21 March is set to accelerate advanced therapy development in the UK. The scheme aims to support UK advanced therapy medicinal product (ATMP) clinical trials. UK Health Minister Andrew Stephenson commented on the news, stating that the investment “reaffirms the UK’s position as a global leader in clinical research”.
STAT
APRIL 4, 2024
Cochlear implants have successfully improved hearing loss for decades, but few people who qualify for an implant actually get it. Even in countries with universal healthcare, the adoption rates are dismal. Researchers are finding further disparities for marginalized communities, especially for Black and Asian patients, according to a recent study of British hospitals published Thursday in PLOS Medicine.
European Pharmaceutical Review
APRIL 4, 2024
US radiopharmacy network RLS Radiopharmacies is expanding its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by establishing a partnership with global isotope technology company Eckert & Ziegler. As part of the agreement, all 31 of RLS’ radiopharmacies will be produce Gallium-68-based (Ga-68) radiopharmaceuticals by the end of June, the company confirmed.
STAT
APRIL 4, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. First the news: Glen Tullman, currently the CEO Transcarent , has a new, roughly $100 million venture fund, called 62 Ventures.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Express Pharma
APRIL 4, 2024
The companies will join forces to advance the use of precision medicine on a global scale SOPHiA GENETICS, a cloud-native software company in the healthcare space has announced a strategic partnership with Strand Life Sciences to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and inno
STAT
APRIL 4, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey, it’s Meghana. Today, we see how the GLP-1s might be harnessed for Parkinson’s, we learn about species de-extinction efforts, and BIO’s CEO tells us why the U.S. needs to stay on top in biotech.
European Pharmaceutical Review
APRIL 4, 2024
The European Commission (EC) has expanded the approval of Reblozyl ® (luspatercept) to include the first-line treatment of adults with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS ). This indication expansion of Reblozyl covers all EU member states, excluding Great Britain. Bristol Myers Squibb stated that this makes it the fourth authorised indication in Europe for Reblozyl.
STAT
APRIL 4, 2024
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Bankruptcies, restructurings, clinical trial setbacks, and falling stock prices: It’s been a disconcerting week in Biotech Land. Luckily, this newsletter has arrived like a warm hug.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
APRIL 4, 2024
Last week, pharmaphorum editor-in-chief Jonah Comstock travelled to Philadelphia for Reuters Pharma USA. On today’s podcast, he chats with guest host and Deep Dive editor Eloise McLellan about his biggest takeaways from the two-day event.
STAT
APRIL 4, 2024
Top of the morning to you, and a fine one it is. After two days of downpours and strong winds, the Pharmalot campus is now enveloped by sunny skies and pleasant breezes, which is very much a welcome change. To celebrate, we are quaffing cups of stimulation. Our choice today is toasted coconut. As always, you are invited to join us. Meanwhile, we are proud to present our latest list of interesting items for you to peruse.
Pharma Times
APRIL 4, 2024
The fatal, progressive neurological condition currently affects around 5,000 people in the UK
STAT
APRIL 4, 2024
A federal judge this week dealt a major and likely decisive blow to Safehouse, a Philadelphia nonprofit seeking to open a facility for supervised drug consumption. In a ruling on Wednesday, U.S. District Court Judge Gerald McHugh dismissed the nonprofit’s lawsuit, concluding that Safehouse was not a religious entity and therefore could not claim exemptions to drug laws under the Religious Freedom Restoration Act.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
APRIL 4, 2024
In February, Trialbee announced its Omnichannel Network partnership with Massive Bio, a global leader in AI-enabled patient journey mapping platform to help better connect cancer patients with their oncologists/hematologists in clinical trials.
STAT
APRIL 4, 2024
Why is it surprising when drug executives stay true to their word? And can neoantigen cancer vaccines work? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space.
Outsourcing Pharma
APRIL 4, 2024
In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.
Pharma Times
APRIL 4, 2024
The project will assist researchers and companies in training the technology for healthcare settings
Express Pharma
APRIL 4, 2024
Zena Health plans to strengthen its reach and democratise healthcare in Eastern India Zeno Health, omni channel platform for quality and affordable generic medicines has announced its acquisition of Kolkata-based startup Tablt Pharmacy. As part of its expansion plans, Zeno Health along with Tablt will be strengthening its reach in the states of West Bengal, Odisha, Bihar and Jharkhand.
Expert insights. Personalized for you.
353 
Let's personalize your content